Yuri Pikover Net Worth

The estimated Net Worth of Yuri Pikover is at least $664 Thousand dollars as of 29 March 2018. Yuri Pikover owns over 3,734 units of Savara Inc stock worth over $664,131 and over the last 7 years Yuri sold SVRA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Yuri Pikover SVRA stock SEC Form 4 insiders trading

Yuri has made over 3 trades of the Savara Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Yuri bought 3,734 units of SVRA stock worth $33,606 on 29 March 2018.

The largest trade Yuri's ever made was buying 100,000 units of Savara Inc stock on 7 June 2017 worth over $475,000. On average, Yuri trades about 30,747 units every 59 days since 2017. As of 29 March 2018 Yuri still owns at least 153,734 units of Savara Inc stock.

You can see the complete history of Yuri Pikover stock trades at the bottom of the page.

What's Yuri Pikover's mailing address?

Yuri's mailing address filed with the SEC is 6836 BEE CAVE ROAD, BUILDING III, SUITE 200, AUSTIN, TX, 78746.

Insiders trading at Savara Inc

Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.

What does Savara Inc do?

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com

Complete history of Yuri Pikover stock trades at Savara Inc

Savara Inc executives and stock owners

Savara Inc executives and other stock owners filed with the SEC include:

• Dr. Badrul A. Chowdhury M.D., Ph.D.,
  Chief Medical Officer
• David Lowrance,
  Chief Financial Officer, Secretary
• David L. Lowrance,
  CFO & Sec.
• Ricky Sun,
  Independent Director
• Annigje van Es-Johansson,
  Independent Director
• Badrul Chowdhury,
  Chief Medical Officer
• Anne Erickson,
  IR Contact Officer
• David Ramsay,
  Independent Director
• Matthew Pauls,
  Chairman of the Board, Interim Chief Executive Officer
• Joseph McCracken,
  Independent Director
• Richard Hawkins,
  Independent Director
• Nevan Elam,
  Independent Director
• Dr. Peter Clarke Ph.D.,
  Exec. VP of Global Technical Operations
• Charles LaPree,
  Sr. VP of Global Regulatory Affairs & Quality Assurance
• Brian Maurer,
  Head of Clinical Operations
• Dr. Dhaval Desai M.D.,
  Head of Clinical Devel.
• Kate McCabe,
  Sr. VP of Legal Affairs
• Robert N Neville,
  Chief Executive Officer
• Yuri Pikover,
  Director
• Jaakko Taneli Jouhikainen,
  See Remarks
• Es Johansson An Van,
  Director
• Forest Baskett,
  10% owner
• Equity Opportunities 17, Ll...,
  
• Rick Yang,
  10% owner
• Paul Edward Walker,
  10% owner
• Scott D Sandell,
  10% owner
• Edward T Mathers,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Carmen Chang,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ali Behbahani,
  10% owner
• Raymond Dennis Pratt,
  Chief Medical Officer
• Robert Matthew Lutz,
  Chief Operating Officer